Battaglia, Alessandra http://orcid.org/0000-0001-7179-8900
Buzzonetti, Alexia
Fossati, Marco
Scambia, Giovanni
Fattorossi, Andrea
Madiyalakan, Madi R.
Mahnke, Yolanda D.
Nicodemus, Christopher
Article History
Received: 6 May 2019
Accepted: 13 December 2019
First Online: 3 January 2020
Change Date: 26 March 2020
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake.
Compliance with ethical standards
:
: Yolanda D. Mahnke is an immunology advisor to OncoQuest. Christopher Nicodemus is a consultant to OncoQuest, Inc. and owns shares in Quest PharmaTech, Edmonton Alberta. Madi R. Madiyalakan is an employee of OncoQuest Inc. and Quest PharmaTech and owns shares in OncoQuest Inc. and Quest PharmaTech. The authors declare that there is no other conflict of interest.
: This QPT-ORE-002 study (clinical trial information: NCT01616303) was performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. It was approved by the following institutional ethics committees:Table removed
: All patients included in the study provided written informed consent according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. The informed consent, which included consent to the treatment, use of their biological specimen (peripheral blood) and data acquisition and processing, was obtained from patients prior to the initiation of the study.